Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360678 | 1.00 | KLK7 (0.66) | KLK7CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL12047330 | 0.87 | KLK7 (0.64) | KLK7CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL27718810 | 0.84 | KLK7 (0.60) | KLK7CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL360231 | 0.81 | KLK7 (0.54) | KLK7CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL360232 | 0.81 | KLK7 (0.54) | KLK7CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL2859436 | 0.81 | KLK7 (0.57) | KLK7CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL2859574 | 0.81 | KLK7 (0.57) | KLK7CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL2864946 | 0.81 | KLK7 (0.57) | KLK7CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL18354326 | 0.80 | KLK7 (1.00) | KLK7POLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL23397715 | 0.79 | ALDH1A1 (0.58) | KLK7ALDH1A1HSD17B10CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407447-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER | TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-8552215-B2 | Method for producing optically active 2-hydroxy ester and novel intermediate compound | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2407447-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | Tokyo University Of Science Educational Foundation Administrative Organization (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319650-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319650-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | CA7, HAO2, HACL2 | KLK7 3948/4885CHRM1 948/4885CHRM3 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.